Advanced Oxygen Therapy
- Company typePublic
- Founded2006
- HeadquartersOceanside, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Advanced Oxygen Therapy does
Advanced Oxygen Therapy Inc. (AOTI) is a publicly traded medical device company (AIM: AOTI, IPO June 2024) that develops and commercializes advanced wound care therapies for chronic non-healing wounds, including diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers. The company is headquartered in Oceanside, California, manufactures at a facility in Galway, Ireland, and operates regional sales/marketing offices in Poole (UK) and St. Petersburg, FL.
AOTI's core technology is the Topical Wound Oxygen (TWO2) multi-modality therapy system, which combines pressurized oxygen delivery (~800 mmHg partial pressure), non-contact cyclical compression (7.5–37.5 mmHg), and fine particulate humidification in a single patient-applied system delivered through two form factors: the Extremity Chamber for leg/foot wounds and the Multi-Patch for wounds elsewhere on the body. The company has expanded its portfolio with the NEXA Negative Pressure Wound Therapy (NPWT) system — a multi-week, multi-patient disposable device with a patented SmartFlow connector and Hydrodynamic Fluid Pump — and supports both platforms with the Engaged Outcomes digital service for remote therapy monitoring, wound imaging, and virtual patient support.
AOTI monetizes primarily through hardware sales of TWO2 and NEXA devices and consumables, reimbursed via a combination of government healthcare payors (US Veterans Administration under a five-year Federal Supply Schedule contract, state Medicaid programs, UK NHS Supply Chain framework) and commercial payors. The company sells through direct enterprise field sales to clinicians, hospital systems, and wound care specialists, and supports patients at home through a dedicated Therapy Support Team that delivers, sets up, and trains on equipment. The company has 11–50 employees and serves over 20,000 patients across the US, UK, Ireland, Germany, the Middle East/Africa/India region, Asia Pacific, and Latin America.
Advanced Oxygen Therapy firmographics
Firmographics- Name
- Advanced Oxygen Therapy
- Legal name
- AOTI Inc.
- Website
- https://aotinc.net
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Advanced Oxygen Therapy industry classification
Industry- Product category
- Advanced Wound Care Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Negative Pressure Wound Therapy (NPWT) Systems & Accessories (HLAHALAB)
- akta.pro secondary industry
- Wound Care & Ulcer Management (HLAKACAN)
Keywords
Where Advanced Oxygen Therapy is headquartered
LocationHeadquarters
- HQ city
- Oceanside
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Advanced Oxygen Therapy business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Sales: Sale of TWO2 therapy systems (Extremity Chamber and Multi-Patch) and NEXA NPWT systems to healthcare providers, patients, and institutional buyers (hospitals, VA, home care settings)
- Healthcare Reimbursement: Revenue through reimbursement from Veterans Administration, Medicaid programs, NHS, and other government healthcare systems under various contracts and supply agreements
Go-to-market motion1 record
Distribution channels5 records
Marketing channels9 records
Advanced Oxygen Therapy product offering
Product offeringCore offering
Advanced Oxygen Therapy (AOTI) manufactures and sells patented wound care medical devices, primarily the TWO2® Topical Wound Oxygen therapy platform (Extremity Chamber and Multi-Patch delivery systems) and the NEXA™ Negative Pressure Wound Therapy (NPWT) system, designed for treating chronic and acute non-healing wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers. The products are complemented by the Engaged Outcomes digital patient engagement platform that provides remote therapy monitoring and home setup/training support via AOTI's Therapy Support Team.
Product overview
Advanced Oxygen Therapy (AOTI) offers a portfolio of clinically-proven wound healing medical devices centered around two core therapy platforms: the Topical Wound Oxygen (TWO2®) multi-modality therapy system and the NEXA™ Negative Pressure Wound Therapy (NPWT) system. The TWO2 platform delivers pressurized oxygen, non-contact cyclical compression, and humidification directly to chronic and acute wounds through two delivery methods: the Extremity Chamber (for wounds on legs/feet) and the Multi-Patch (for wounds across the body). The NEXA NPWT system is a disposable negative pressure wound therapy device. Both platforms are supported by the Engaged Outcomes digital service for remote patient monitoring and therapy support. All products are FDA cleared.
Differentiator
Problem solved
Functional benefit
Brands
- TWO2: Topical Wound Oxygen therapy system for chronic wound healing, including the Extremity Chamber and Multi-Patch products.
- NEXA
- Engaged Outcomes
Products and services
- TWO2® Topical Wound Oxygen Therapy Platform A multi-modality patient-administered wound therapy platform that delivers pressurized oxygen, non-contact cyclical compression, and humidification directly to chronic and acute wounds. Includes the Extremity Chamber and Multi-Patch delivery systems and is intended for clinicians treating diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
- TWO2® Extremity Chamber A chamber-based system that delivers cyclical pressurized topical oxygen therapy to wounds on the lower extremities. Available in medium and large sizes to accommodate wounds from the lower two-thirds of the leg up to the knee. Used with conventional compression dressings, UNNA boots, or total contact casts by wound care clinicians for DFU and VLU treatment.
- TWO2® Multi-Patch A flexible, patch-based system that can be sized and customized to accommodate a wide variety of ulcer sizes or shapes and applied almost anywhere on the body. Delivers a 5-fold increase in pO2 to amplify local immune response, stimulate angiogenesis, and enhance collagen synthesis. Not available in the EU region.
- NEXA™ NPWT System A multi-week, multi-patient, disposable Negative Pressure Wound Therapy (NPWT) system designed for use in home, acute, and extended care settings. Features single-button operation, approximately 10-hour battery life, and a 56-day operational lifespan. Includes patented Hydrodynamic Fluid Pump and SmartFlow™ Connector innovations for multi-patient use and seamless hospital-to-home transition. FDA 510(k) cleared July 2024 for home care use.
- Engaged Outcomes (Eyes on the Wound) A digital patient engagement platform that provides remote therapy monitoring, virtual therapy support, and wound imaging services for patients receiving TWO2 and NEXA therapy at home. Includes at-home therapy patient-applied daily with support from the AOTI Therapy Support Team for equipment set-up, training, and ongoing patient engagement.
Quantifiable outcome
- 88% reduction in hospitalizations for DFU patients treated with TWO2 therapy
- +7 more outcomes
Companies that use Advanced Oxygen Therapy
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Advanced Oxygen Therapy technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Advanced Oxygen Therapy partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and secondary.
- National Health Service (NHS)coreTWO2 therapy included in NHS supply chain framework agreement for 2025, enabling distribution through UK healthcare system to NHS patients.
- Veterans Administration (VA)coreAOTI awarded five-year extension to Veterans Administration contract (contract number: 36F79719D0186) covering TWO2 therapy reimbursement for Veterans. VA is the largest Integrated Health Network in the USA serving 23 million Veterans.
- Amputation Prevention Alliance (APA)corePartnership focused on preventing unnecessary amputations for diabetic patients through enhancing education and healthcare accessibility. AOTI is a Founding Partner. Through this partnership, the companies are educating decision-makers and state agencies about the science and successes of Topical Oxygen Therapy.
- Society for Vascular Surgery (SVS)corePartnership focused on transforming vascular health through research, innovation and comprehensive care. AOTI participates in Society for Vascular Surgery Annual Meeting.
- American Limb Preservation Society (ALPS)corePartnership dedicated to eliminating preventable amputations over the next generation through advancements in science and clinical care.
- American Diabetes Association (ADA)coreADA awarded Topical Oxygen Therapy an A-grade adjunctive treatment recommendation for diabetic foot ulcers. Partnership includes Amputation Prevention Alliance collaboration and participation in ADA Scientific Sessions.
- American Academy of Home Care Medicine (AAHCM)secondaryPartnership focused on delivering interdisciplinary, high-value health care in the home for all people in need by promoting the art, science, and practice of home care medicine.
- American Venous Forum (AVF)secondaryPartnership focused on improving the care of patients with venous and lymphatic disease through research and clinical advancement.
Scale indicators10 records
Recent moves1 record
Expansion highlights6 records
Advanced Oxygen Therapy competitors and assessment
Company assessmentDirect peers
- Smith+Nephew: Global medical device company with a substantial Advanced Wound Management portfolio including the PICO single-use NPWT system. Directly comparable to AOTI in NPWT and chronic wound care for hospital, community, and home settings.
- Solventum (formerly 3M Health Care / KCI): Inventor of V.A.C. negative pressure wound therapy and a leading global wound care franchise. Most directly comparable NPWT competitor to AOTI's NEXA system, with broad hospital and home-care channel coverage.
- Mölnlycke Health Care: Swedish wound care and surgical solutions company offering Mepilex dressings and Avance NPWT systems. Competes head-to-head with AOTI in chronic wound management across hospital and home-care channels.
- ConvaTec Group: Publicly-listed wound care, ostomy, and continence device company with an advanced wound care portfolio including foam dressings and NPWT products. Comparable to AOTI's TWO2/NEXA positioning for chronic wound patients.
Broad incumbents
- Coloplast: Danish medical device company with a significant wound care business (Biatain dressings) alongside ostomy and continence. Overlaps with AOTI in advanced wound care for chronic wounds across similar customer segments.
- Integra LifeSciences: Publicly-listed medical technology company with a dedicated Wound Care and Tissue Reconstruction portfolio including dermal matrices and skin grafts. Targets the same chronic and complex wound market as AOTI's TWO2 therapy.
- Organogenesis Holdings: Publicly-traded regenerative medicine company focused on advanced wound care and surgical biologics (Apligraf, Dermagraft). Comparable to AOTI in serving chronic wound patients (DFU, VLU) with clinically differentiated products.
Emerging players
- MiMedx Group: Publicly-traded company commercializing placental tissue allografts (EpiFix, AmnioFix) for chronic wound care and surgical recovery. A niche/emerging competitor targeting similar DFU/VLU patient populations as AOTI.
Others
- Cardinal Health: Major US medical products distributor that supplies wound care products, NPWT devices, and dressings to hospitals, home health agencies, and DME providers — overlapping with AOTI's distribution channel and customer base.
Regional players
- Paul Hartmann AG: German medical and wound care company with a strong European footprint (HydroTherapy, RespoSorb, Atrauman). Operates in similar wound care categories as AOTI, with primary geographic overlap in Germany and broader EU markets.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks7 records
Key highlights6 records
Customer concentration
Advanced Oxygen Therapy social profiles
Digital presenceAdvanced Oxygen Therapy compliance and trust
Trust signalCompliance4 records
Advanced Oxygen Therapy financial estimates
Financial estimateRevenue estimate
Valuation estimate
Advanced Oxygen Therapy leadership team
Management profileNumber of profiles
Profiles14 records
Advanced Oxygen Therapy subsidiaries and ownership
Company hierarchySubsidiaries1 record
Advanced Oxygen Therapy funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Advanced Oxygen Therapy M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Advanced Oxygen Therapy
What does Advanced Oxygen Therapy do?
Advanced Oxygen Therapy (AOTI) manufactures and sells patented wound care medical devices, primarily the TWO2® Topical Wound Oxygen therapy platform (Extremity Chamber and Multi-Patch delivery systems) and the NEXA™ Negative Pressure Wound Therapy (NPWT) system, designed for treating chronic and acute non-healing wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers. The products are complemented by the Engaged Outcomes digital patient engagement platform that provides remote therapy monitoring and home setup/training support via AOTI's Therapy Support Team.
Is Advanced Oxygen Therapy a public or private company?
Advanced Oxygen Therapy is a public company. It is classified as public and is currently operating.
When was Advanced Oxygen Therapy founded?
Advanced Oxygen Therapy was founded in 2006. It employs 11 to 50 people.
Where is Advanced Oxygen Therapy based?
Advanced Oxygen Therapy is headquartered in Oceanside, United States, in the North America region.
How does Advanced Oxygen Therapy make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are healthcare Reimbursement.
Who are Advanced Oxygen Therapy's main competitors?
Direct peers on record are Smith+Nephew, Solventum (formerly 3M Health Care / KCI), Mölnlycke Health Care and ConvaTec Group. Broad incumbents are Coloplast, Integra LifeSciences and Organogenesis Holdings. MiMedx Group is listed as an emerging player. Cardinal Health is listed as an others. Paul Hartmann AG is listed as a regional player.
Does Advanced Oxygen Therapy have an API?
No public API is recorded for Advanced Oxygen Therapy.
What industry is Advanced Oxygen Therapy in?
Advanced Oxygen Therapy's product category is Advanced Wound Care Medical Devices. Its primary akta.pro industry code is HLAHALAB, Negative Pressure Wound Therapy (NPWT) Systems & Accessories, with a secondary code of HLAKACAN, Wound Care & Ulcer Management. Its NAICS code is 334510 and its SIC code is 3841.